Signpath Pharma is a development stage biotechnology company founded in 2006. Its lead compound is 99.2% pure synthesized curcumin (diferuloylmethane). Curcumin has an extensive and long history in humans as a mixture of naturally occurring curcuminoids in extracts of the root of the Curcuma longa plant. Traditional use of curcumin has been restricted to topical skin and gastrointestinal conditions because of negligible absorption when given orally. To extend its clinical use Signpath is developing three different intravenous nanoparticle-sized formulations; liposomal, polymeric, and PLGA. Proof of efficacy of these formulations against human tumor xenografts in mice has been established. Following intravenous injection of each formulation, we observed transport across the blood brain barrier in mice, rats, and localization in the hippocampus, brainstem and the striatum.

from http://signpathpharma.com/

Patents 95show all

  • 44
    A61K - Preparations for medical, dental, or toilet purposes
  • 16
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 7
    C07C - Acyclic or carbocyclic compounds
  • 4
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
  • 1
    A61B - Diagnosis
  • 1
    Y02A - Technologies for adaptation to climate change

Clinical Trials 2show all

1Phase 11Phase 1/Phase 2

SEC Filings show all


22
10-Q

11
8-K

7
10-K

7
D

1
S-1

Contact Information

1375 California RD
Quakertown, PA 18951
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$7,294,5761-102016-01-27Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2011-10-04$580,000Series Unknown
2016-01-27$2,359,076Series Unknown
2014-06-05$4,355,500Series Unknown